A biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer - Lorus Therapeutics Inc. ("Lorus") (TSE: LOR) - presented the pharmacokinetics of GTI-2040 in patients with acute myeloid leukemia at the American Association of Pharmaceutical Scientists (AAPS) Meeting in San Antonio, TX (October 29 - November 2, 2006).
The uptake of GTI-2040 in distinct subcellular compartments of leukemic cells at levels that exceeded plasma levels, measured through an ultra-sensitive analytic method has been presented in a report entitled "Population Pharmacokinetics (PK) of GTI-2040 in Patients with Acute Myeloid Leukemia (AML)".
The results of this study identified specific patterns of intracellular distribution of the parent drug predictive of both biologic and clinical responses.
These data are consistent with previous findings, showing that GTI-2040 levels in circulating leukemic cells were 2.7 times higher and more sustained than values seen in plasma.
The levels were even greater in leukemic blast cells in bone marrow, which is the primary target tissue in the treatment of leukemia.
An antisense drug, GTI-2040 specifically targets the R2 component of ribonucleotide reductase, which is required for DNA synthesis and cell proliferation.
Find more details of the clinical data from the press release (a pdf file).
Comment Preview